Sanofi targeted in vaccine pricing suit; Seattle Genetics lays groundwork for wider Adcetris approval;

 @FiercePharma: Packaging veteran urges including patient in drug pedigree chain. Story | Follow@FiercePharma

> Glenmark Pharma seeks arbitration to get Napo Pharmaceuticals to keep to a collaboration agreement between the two companies. Article

> New York's governor signs a bill that takes aim at mail-order pharmacies. Report

> Sanofi ($SNY) is named in suit over meningococcal vaccine pricing practices. Item

> Biopharma companies shutter 38 plants in 2011, down from 65 in 2010. Report

> Seattle Genetics' lymphoma drug Adcetris could gain approval for use in a larger market after a small study showed its benefits when used with other therapies. Item

Biotech News

 @FierceBiotech: In another rare disease push, GSK is teaming with University of Dundee researchers to find Huntingdon's treatment. Report | Follow @FierceBiotech

 @JohnCFierce: Strong arguments from Harvard's Carpenter on making FDA independent. Not gonna happen, but it's an intelligent piece. Article | Follow @JohnCFierce

> Drug companies steer toward automakers for advice. Story 

> Venture survey forecasts tough life sciences investment scene for 2012. Item 

Drug Delivery News

> Immunomedics promotes 2 cancer treatments to later-stage trials. News

> India university creates low-cost insulin pump: commercial partners wanted. Report

> Nanoparticles carting steroids to retina delay macular degeneration. Item

> Silk may be basis for smoothest microneedle system yet. Article

Biomarkers News

> Biomarkers provide route to personalized medicine. Piece

> BNP may serve as prognostic biomarker in valve disease. News

> Next-gen sequencing pinpoints breast cancer biomarkers. Story

> Diabetes collaboration to identify biomarkers. Item

Medical Devices News

> Infrascan gets FDA's OK for hematoma detector. News

> Ventana, ACD ink co-promotion deal. Item

> Final Synthes exec sentenced in Norian case. Report

> Baxter enters agreement to buy Synovis for $325M. Article

And Finally... The FDA is cracking down on the marketing practices of 1-800-GET-THIN. Article

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.